Teleflex has secured FDA approval for its EZPLAZ Freeze Dried Plasma and completed a $1.5 billion OEM divestiture, refocusing its portfolio. The stock has gained 13.71% over the past 90 days and delivered a 23.40% one-year total shareholder return. A widely followed analyst narrative estimates fair value at $148.55, slightly above the last close of $140.12, implying the stock is modestly undervalued. That narrative assumes annual revenue growth of 6.1% over the next three years and a profit margin recovery from 0.1% to 11.7%, though execution risks remain if UroLift weakness persists or Biotronik integration pressures margins.
Teleflex IncorporatedFDA approval for EZPLAZ Freeze Dried Plasma and completed OEM divestiture refocus portfolio.
